AVEO Pharmaceuticals Inc. (AVEO)

0.62
0.01 1.18
NASDAQ : Health Technology
Prev Close 0.61
Open 0.61
Day Low/High 0.60 / 0.63
52 Wk Low/High 0.56 / 3.59
Volume 1.44M
Avg Volume 3.58M
Exchange NASDAQ
Shares Outstanding 139.00M
Market Cap 84.79M
P/E Ratio N/A
Div & Yield N.A. (N.A)
AVEO Oncology Announces Completion Of TIVO-3 Study Futility Analysis With No Changes To Study Protocol

AVEO Oncology Announces Completion Of TIVO-3 Study Futility Analysis With No Changes To Study Protocol

AVEO Oncology (NASDAQ:AVEO) today announced the completion of a pre-planned futility analysis of the Phase 3 TIVO-3 trial, the Company's randomized, controlled, multi-center, open-label study to compare FOTIVDA ®...

Biotech Names Flexing Their Muscles

Biotech Names Flexing Their Muscles

There's action in Global Blood Therapeutics and Antares Pharma.

AVEO Oncology And EUSA Pharma Announce TiNivo Combination Study Opt-in

AVEO Oncology And EUSA Pharma Announce TiNivo Combination Study Opt-in

AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma today announced that EUSA Pharma, under its multi-territory licensing agreement with AVEO for FOTIVDA ® (tivozanib), has opted into the Phase 1/2 TiNivo study.

AVEO Oncology Announces Receipt Of Payments From EUSA Pharma And CANbridge

AVEO Oncology Announces Receipt Of Payments From EUSA Pharma And CANbridge

AVEO Oncology (NASDAQ:AVEO) today announced the receipt of a $4 million research and development payment from EUSA Pharma related to the approval of FOTIVDA ® (tivozanib) for the treatment of adult patients with...

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I've Prepared for Hurricane Irma -- and a Market Pullback

As a Miami resident, I've learned the value of hurricane preparation and the 'Jensen Rules'.

How I'm Prepared for Irma -- and a Pullback

How I'm Prepared for Irma -- and a Pullback

As a Florida resident, I've learned the value of preparation and the 'Jensen Rules'.

AVEO Oncology To Present At Upcoming Conferences

AVEO Oncology To Present At Upcoming Conferences

AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will be presenting at the following investor conferences: The 19 th Annual Rodman & Renshaw...

AVEO Oncology Announces FOTIVDA® (tivozanib) Approved In The European Union For The Treatment Of Advanced Renal Cell Carcinoma

AVEO Oncology Announces FOTIVDA® (tivozanib) Approved In The European Union For The Treatment Of Advanced Renal Cell Carcinoma

AVEO Oncology (NASDAQ: AVEO) today announced that the European Commission (EC) has approved FOTIVDA ® (tivozanib) for the treatment of adult patients with advanced renal cell carcinoma (RCC) in the European Union plus...

AVEO Reports Second Quarter 2017 Financial Results And Provides Business Update

AVEO Reports Second Quarter 2017 Financial Results And Provides Business Update

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2017, and provided a business update.

AVEO Oncology Announces $14M In Aggregate Gross Proceeds From Hercules Credit Facility And At-the-market Stock Offerings

AVEO Oncology (NASDAQ:AVEO) today announced that it has secured $14 million in aggregate gross proceeds through its credit facility with Hercules Capital, Inc.

AVEO Oncology Announces Positive CHMP Opinion For Tivozanib As A Treatment Of Advanced Renal Cell Carcinoma

AVEO Oncology (NASDAQ:AVEO) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has recommended FOTIVDA™ (tivozanib) for...

AVEO Oncology Announces Pivotal Phase 3 TIVO-3 Study Of Tivozanib In Renal Cell Carcinoma Reaches Enrollment Target

AVEO Oncology (NASDAQ: AVEO) today announced that the Company's pivotal TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal...

AVEO Oncology Announces Phase 1/2 TiNivo Trial Of Tivozanib And Opdivo® (nivolumab) In RCC Advances To Phase 2

AVEO Oncology (NASDAQ:AVEO) today announced that its Phase 1/2 AVEO-sponsored TiNivo trial evaluating tivozanib in combination with Bristol-Myers Squibb's anti-PD-1 therapy, Opdivo ® (nivolumab), in subjects with...

AVEO Oncology And Biodesix Announce Results From Two Investigator-Sponsored Phase 1 Studies Of HGF Targeted Antibody Ficlatuzumab At The 2017 ASCO Annual Meeting

AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc., co-development partners, today announced the presentation of results from two investigator-sponsored Phase 1 studies of ficlatuzumab at the 2017 American Society of...

AVEO Oncology Announces Completion Of A CHMP Oral Explanation For Tivozanib As A Treatment Of First-Line Renal Cell Carcinoma

AVEO Oncology (NASDAQ:AVEO) today announced its European licensee for tivozanib, EUSA Pharma, has completed an oral explanation to the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the...

AVEO Announces Appointment Of Matthew Dallas As Chief Financial Officer

AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Matthew Dallas as chief financial officer, effective June 1, 2017.

AVEO Issues Statement Regarding The Passing Of Lead Director Henri A. Termeer

The Board of Directors of AVEO Oncology (NASDAQ:AVEO) today issued the following statement regarding the passing of its Lead Director Henri A.

AVEO Oncology Announces Receipt Of USPTO Notice Of Allowance Related To AV-353

AVEO Oncology (NASDAQ: AVEO) today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.

AVEO Reports First Quarter 2017 Financial Results And Provides Business Update

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2017, and provided a business update.

AVEO Announces Presentations At The 2017 ASCO Annual Meeting

AVEO Oncology (NASDAQ:AVEO) today announced that poster presentations for three clinical studies will be presented at the upcoming 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2-6, 2017.

AVEO Announces Submission Of Response To Tivozanib Marketing Authorization Application Day 180 List Of Outstanding Issues

AVEO Oncology (NASDAQ: AVEO) today announced that its European licensee for tivozanib, EUSA Pharma, has submitted responses to the European Medicines Agency (EMA) Day 180 List of Outstanding Issues (LOI) related to the...

AVEO Announces Milestone Payment From CANbridge For AV-203

AVEO Oncology (NASDAQ:AVEO) today announced receipt of a $500,000 milestone payment from CANbridge Life Sciences Ltd.

AVEO Announces Closing Of Public Offering And Full Exercise Of Option To Purchase Additional Shares

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) today announced the closing of its previously announced underwritten public offering of 34,500,000 shares of common stock, including the exercise in full by the underwriter of its...

AVEO Announces Pricing Of $15.0 Million Public Offering Of Common Stock

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has priced an underwritten public offering of 30,000,000 shares of common stock at a price to the public of $0.

AVEO Announces Proposed Offering Of Common Stock

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

AVEO Reports Full Year 2016 Financial Results And Provides Business Update

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2016 and provided a business update.

AVEO Announces First Patient Dosed In Phase 1/2 TiNivo Trial Of Tivozanib And Opdivo® (nivolumab) In Advanced RCC

AVEO Oncology (NASDAQ:AVEO) today announced that the first patient has been dosed in the Phase 1/2 AVEO-sponsored TiNivo trial evaluating tivozanib in combination with Bristol-Myers Squibb's anti-PD-1 therapy, Opdivo®...

AVEO Announces TIVO-3 Passes The First Safety Monitoring Committee Safety Review

AVEO Oncology (NASDAQ:AVEO) today announced that its pivotal, Phase 3 TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell...

AVEO Announces Clinical And Regulatory Updates For Tivozanib

AVEO Oncology (NASDAQ:AVEO) today announced clinical and regulatory updates for its lead drug candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI).

AVEO To Present At The 19th Annual BIO CEO & Investor Conference

AVEO Oncology (NASDAQ:AVEO) today announced that Michael Needle, M.

TheStreet Quant Rating: D- (Sell)